# Arda Therapeutics

> Targeted cell-depletion therapies for chronic diseases using oncology modalities outside cancer.

## Why it is interesting

Applying ADC and T-cell engager approaches to fibrosis and immunology — single-cell biology engine to selectively remove pathogenic cell populations.

## Profile

- **Stage:** series-a
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (2024): $43M led by a16z with Two Sigma Ventures, GV, Eli Lilly (Business Wire)
- Seed (2022): a16z Bio + Health led at inception (a16z announcement)
- Thesis: ADC/TCE cell depletion for fibrosis and immunology beyond oncology (Arda site)
- Co-investors not in VCT directory: GV (Google Ventures), Eli Lilly

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/two-sigma-ventures
- https://venturecapitaltracker.com/fund/first-round

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/arda-therapeutics